Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.446 EUR | -3.96% | -4.28% | -26.99% |
Apr. 11 | Valneva: Deep Track Biotechnology Master holds less than 5% of the capital | CF |
Mar. 26 | Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate | MT |
Business Summary
Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets two proprietary travel vaccines as well as certain third-party vaccines leveraging its established commercial infrastructure.
Revenues from its growing commercial business help fuel the continued advancement of Valneva's vaccine pipeline. This includes the world's first vaccine against the chikungunya virus and the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.
Number of employees: 676
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Development and Commercialization of Prophylactic Vaccines
100.0
%
| - | - | 154 | 100.0 % | - |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
21.4
%
| -24 | -6.6 % | 33 | 21.4 % | -238.49% |
Canada
18.3
%
| 19 | 5.2 % | 28 | 18.3 % | +49.14% |
United Kingdom
13.2
%
| 181 | 50.2 % | 20 | 13.2 % | -88.81% |
Rest of World
10.6
%
| 17 | 4.8 % | 16 | 10.6 % | -6.06% |
Austria
9.5
%
| 21 | 5.9 % | 15 | 9.5 % | -30.92% |
Germany
8.8
%
| 69 | 19.0 % | 14 | 8.8 % | -80.30% |
Nordics
8.3
%
| 12 | 3.3 % | 13 | 8.3 % | +5.69% |
Other Europe
6.1
%
| 19 | 5.2 % | 9 | 6.1 % | -50.19% |
France
3.8
%
| 47 | 12.9 % | 6 | 3.8 % | -87.39% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 13-05-09 | |
Peter Buhler
DFI | Director of Finance/CFO | 54 | 21-07-28 |
Vincent Dequenne
COO | Chief Operating Officer | - | 21-07-05 |
Chief Tech/Sci/R&D Officer | 53 | 20-09-30 | |
Investor Relations Contact | - | 13-05-31 | |
Dipal Patel
PRN | Corporate Officer/Principal | - | 22-11-16 |
Frédéric Jacotot
LAW | General Counsel | 60 | 17-03-31 |
Franck Grimaud
PRN | Corporate Officer/Principal | 58 | 13-05-09 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kathrin Jansen
BRD | Director/Board Member | - | 23-06-20 |
James Sulat
BRD | Director/Board Member | 73 | 13-03-06 |
Jim Connolly
BRD | Director/Board Member | 59 | 22-06-23 |
Chief Executive Officer | 60 | 13-05-09 | |
Maïlys Ferrère
BRD | Director/Board Member | 60 | 22-06-23 |
Peter Buhler
DFI | Director of Finance/CFO | 54 | 21-07-28 |
Chairman | 62 | 13-03-06 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 138,912,142 | 116,329,893 ( 83.74 %) | 124,322 ( 0.0895 %) | 83.73 % |
Stock B | 0 | 20,514 | 0 | 0 |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
VALNEVA 0.09% | 124,322 | 0.09% | 488,332 $ |
Company contact information
Valneva SE
Campus Bio-Ouest 6, rue Alain Bombard
44800, Saint-Herblain
+33 2 28 07 37 10
http://www.valneva.comGroup companies
Name | Category and Sector |
---|---|
Valneva Austria GmbH
Valneva Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The private company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013. |
Miscellaneous Commercial Services
|
Valneva Sweden AB
Valneva Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers. |
Biotechnology
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.99% | 532M | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- VLA Stock
- Company Valneva